Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.
Why it matters: Neurocrine's acquisition of Soleno Therapeutics marks its entry into the competitive obesity drug market.
- Neurocrine Biosciences is reportedly nearing a deal to acquire Soleno Therapeutics.
- Soleno Therapeutics’ stock is soaring in premarket trading on Monday following the acquisition report.
- The acquisition is intended to accelerate Neurocrine's development of new obesity drugs.
Neurocrine Biosciences is reportedly on the verge of acquiring Soleno Therapeutics, a move signaling Neurocrine's strategic entry into the obesity drug development market. This potential acquisition has already triggered a significant premarket surge in Soleno Therapeutics' stock.
